Lyell Immunopharma, Inc.

NASDAQ:LYEL

Biotechnology

Healthcare
$13.89 +1.20%

+$0.15 today

Market cap
$341.49M
Beta
-0.09
P/E (TTM)
-1.1
EPS (TTM)
-$11.26
52W Low $8.46High $45.00

Volume 0.11M

Average 0.09M

LYEL Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

Lyell Immunopharma, Inc.NASDAQ: LYEL

Accounts Payables · Q1 FY2026 · quarter ended Mar 2026

Accounts payables turns positive

Q1 FY2026 accounts payables was $2.38M, compared with -$1.65M a year earlier. Trailing-twelve-month accounts payables was $1.7M.

Context

  • Accounts payables amounted to 6497.2% of revenue in FY2025, up 1195.6 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly accounts payables holds near $2.38M or moves back toward the trailing-twelve-month quarterly average of $424.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.38M+633.2% QoQ
Last fiscal yearDec 2025
-$2.34M-27.7% YoY
LTMMar 2026
$1.7M+135.6% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+244.1%——
1 year-27.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(2.34M) USD
Year-over-year change
+27.7%

Accounts Payables vs competitors

How LYEL compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +135.6% is the 2nd highest of 9, against a peer median of -17.8%.
  • Accounts payables amounts to 5477.4% of revenue for LYEL, versus a peer median of 9.2%.
LYEL Competitors
Accounts Payables for LYEL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$17.22M USD+128.8%—8.0%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$5.87M USD+736.9%+375.3%—
SLNSilence Therapeutics plcLTM Mar 2026$5.6M USD——608.1%
KYTXKyverna Therapeutics, Inc.LTM Mar 2026$3.03M USD+109.0%-7.1%—
LYELLyell Immunopharma, Inc.LTM Mar 2026$1.7M USD+135.6%—5477.4%
EDITEditas Medicine, Inc.LTM Mar 2026$1.13M USD+32.3%—2.9%
GNLXGenelux CorporationLTM Mar 2026$594K USD-134.0%—7425.0%
ACIUAC Immune S.A.LTM Dec 2025CHF 327.34K CHF——9.2%
CABACabaletta Bio, Inc.LTM Mar 2026$310K USD-132.7%——
ALLOAllogene Therapeutics, Inc.LTM Mar 2026$232K USD-67.8%——
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$204.79K USD-411.0%-70.8%—
Peer median (excluding LYEL) —-17.8%-7.1%9.2%

Competitors are the stored peer set for LYEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(250.22M)(183.12M)(234.63M)(342.99M)(274.45M)
Depreciation & Amortization13.62M16.47M20.25M19.63M11.54M
Deferred Income Tax39.51M0000
Stock-Based Compensation62.2M047.08M33.14M41.83M
Change in Working Capital4.02M(82.02M)3.42M(3.12M)(9.89M)
Accounts Receivables00000
Inventory00000
Accounts Payables91K667K1.46M(3.23M)(2.34M)
Other Working Capital3.92M(82.68M)1.96M114K(7.56M)
Other Non-Cash Items4.62M79.11M183K130.95M80.95M
Operating Cash Flow(126.25M)(169.56M)(163.69M)(162.39M)(150.02M)
Capital Expenditures(65.5M)(24.28M)(2.69M)(464K)(780K)
Acquisitions (Net)673.47M00(31.35M)(41.2M)
Purchases of Investments(673.47M)(406.32M)(476.88M)(394.71M)(259.71M)
Sales of Investments617.4M419.05M663.61M548.94M374.68M
Other Investing Activities(673.47M)000(18.9M)
Investing Cash Flow(121.57M)(11.54M)184.05M122.42M54.1M
Debt Repayment00000
Common Stock Issued391.8M11.1M2.2M1.4M50.41M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities9.44M(461K)(457K)(76K)(1K)
Financing Cash Flow401.24M10.64M1.74M1.33M50.41M
Effect of Forex Changes0186K(4K)00
Net Change in Cash153.42M(170.27M)22.09M(38.64M)(45.52M)
Free Cash Flow(191.75M)(193.83M)(166.38M)(162.86M)(150.8M)

Lyell Immunopharma, Inc.

NASDAQ:LYEL

Intrinsic Alpha fair value

Locked

Current Price

$13.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.